Westfield Capital Management
NVCR icon

Westfield Capital Management’s NovoCure NVCR Stock Holding History

Westfield Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-305,185
Closed -$14.7M – 261
2019
Q1 		$14.7M Sell
305,185
-380,705
-56% -$18.3M 0.11% 190
2018
Q4 		$23M Buy
685,890
+480,085
+233% +$17.6M 0.2% 144
2018
Q3 		$10.8M Sell
205,805
-303,805
-60% -$12.1M 0.08% 198
2018
Q2 		$16M Buy
509,610
+53,575
+12% +$1.49M 0.12% 192
2018
Q1 		$9.94M Sell
456,035
-54,765
-11% -$1.18M 0.08% 200
2017
Q4 		$10.3M Buy
+510,800
New +$9.84M 0.08% 199

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Westfield Capital Management's NVCR Position: Q2 2019 in Review

Westfield Capital Management sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 305,185 shares — an estimated $14.7M sold.

Westfield Capital Management first reported a position in NVCR in Q4 2017 and held it in 6 quarters. The position peaked at $23M in Q4 2018. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

  • Westfield Capital Management reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
  • Westfield Capital Management sold 305,185 NovoCure shares in Q2 2019, an estimated $14.7M.
  • Westfield Capital Management first reported a position in NovoCure in Q4 2017 and held it in 6 quarters.
  • Westfield Capital Management's NovoCure position peaked at $23M in Q4 2018.
  • 197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on Westfield Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.